To print: Select File and then Print from your browser's menu

Title: Sorafenib Plus Low-Dose Interferon-Alpha-2a Shows Clinical Benefit in Metastatic Renal Cell Carcinoma: Presented at ICACT

"Sorafenib Plus Low-Dose Interferon-Alpha-2a Shows Clinical Benefit in Metastatic Renal Cell Carcinoma: Presented at ICACT"

By Shazia Qureshi PARIS, FRANCE -- February 8, 2008 -- Treatment with sorafenib and low-dose interferon alpha-2a resulted in a clinical benefit rate of about 80% in patients with metastatic renal cell carcinoma in a study presented here at the 19th International Congress on Anti-Cancer Treatment (ICACT). The results of this randomised, prospective, phase 2 trial were presented here on February 5 by lead author Sergio Bracarda, MD, Specialist in Medical Oncology and Urology, Santa Maria della Misericordia Hospital, Perugia, Italy. The researchers randomised 100 patients with metastatic renal cell carcinoma (with a clear-cell component of 50% or higher) to one of two study arms, each with a different dosing schedule of interferon alpha-2a. The median age of patients was 63 years (range 34-80 years), and 29% of all patients were women. All patients had previously undergone a nephrectomy and they had no cerebral metastases. All patients were given 400 mg of sorafenib twice daily. Patients assigned to study arm A (n = 51) were given 9 MU of interferon alpha-2a subcutaneously 3 times a week. Patients in arm B (n = 49) received 3 MU of interferon-alpha-2a subcutaneously 5 times a week. In both groups, interferon treatment was started 7 days after the start of sorafenib treatment. The results showed that an objective response was observed in 17.6% of patients in arm A and 34.7% of patients in arm B ([P =.05). In arm A, 47.1% of patients achieved stable disease, compared with 44.9% of patients in arm B. Taken together, Dr. Bracarda said, there was a clinical benefit rate of 64.7% in arm A and 79.6% in arm B (P =.09).

The researchers found that in study arm A, the median progression-free survival was 7.9 months. It was 8.5 months in study arm B (P =.21).

The most commonly occurring severe adverse effects included hypophosphataemia, skin rash, fatigue, diarrhoea, leukopaenia, and thrombocytopenia.

Dr. Bracarda said that while sorafenib plus interferon is a combination that is currently used to treat metastatic renal cell carcinoma, the use of low-dose interferon with sorafenib is a new treatment option that shows good clinical benefit and good tolerability.

[Presentation title: Sorafenib in Combination With Interferon-alpha-2a for Metastatic Renal Cell Carcinoma: Results From a Randomized Prospective Phase II Trial of Two Different Treatment Schedules (RAPSODY; GOIRC Study 0681). Abstract OR 18]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.